Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Acta cir. bras ; 35(4): e202000402, 2020. tab, graf
Article in English | LILACS | ID: biblio-1130629

ABSTRACT

Abstract Purpose To investigate the effects of bradykinin on reperfusion injury in an experimental intestinal ischemia reperfusion model. Methods We used 32 Wistar-Albino rats. We composed 4 groups each containing 8 rats. Rats in sham group were sacrified at 100 minutes observation after laparotomy. Thirty minutes reperfusion was performed following 50 minutes ischaemia in control group after observing 20 minutes. Ischaemic preconditioning was performed in one group of the study. We performed the other study group pharmacologic preconditioning by infusional administration of 10 μg/kg/minute bradykinin intravenously. We sacrified all of the rats by taking blood samples to evaluate the lactate and lactate dehydrogenase (LDH) after resection of jejunum for detecting tissue myeloperoxidase (MPO) activity. Results Lactate and LDH levels were significantly higher in control and study groups than the sham group (P<0.001). There is no difference between the study groups statistically. (P>0.05). The results were the same for MPO levels. Although definitive cell damage was determinated in the control group by hystopatological evaluation, the damage in the study groups observed was lower in different levels. However, there was no significant difference between the study groups statistically (P>0.05). Conclusion Either ischeamic preconditioning or pharmacologic preconditioning made by bradykinin reduced the ischemia reperfusion injury at jejunum.


Subject(s)
Animals , Female , Vasodilator Agents/pharmacology , Bradykinin/pharmacology , Reperfusion Injury/prevention & control , Ischemic Preconditioning/methods , Disease Models, Animal , Intestine, Small/drug effects , Reference Values , Time Factors , Random Allocation , Reproducibility of Results , Treatment Outcome , Rats, Wistar , Peroxidase/analysis , Laparotomy
2.
Braz. j. med. biol. res ; 49(1): 00601, 2016. tab, graf
Article in English | LILACS | ID: lil-765006

ABSTRACT

Drospirenone (DRSP) is a progestin with anti-aldosterone properties and it reduces blood pressure in hypertensive women. However, the effects of DRSP on endothelium-dependent coronary vasodilation have not been evaluated. This study investigated the effects of combined therapy with estrogen (E2) and DRSP on endothelium-dependent vasodilation of the coronary bed of ovariectomized (OVX) spontaneously hypertensive rats. Female spontaneously hypertensive rats (n=87) at 12 weeks of age were randomly divided into sham operated (Sham), OVX, OVX treated with E2 (E2), and OVX treated with E2 and DRSP (E2+DRSP) groups. Hemodynamic parameters were directly evaluated by catheter insertion into the femoral artery. Endothelium-dependent vasodilation in response to bradykinin in the coronary arterial bed was assessed using isolated hearts according to a modified Langendorff method. Coronary protein expression of endothelial nitric oxide synthase and estrogen receptor alpha (ER-α) was assessed by Western blotting. Histological slices of coronary arteries were stained with hematoxylin and eosin, and morphometric parameters were analyzed. Oxidative stress was assessed in situ by dihydroethidium fluorescence. Ovariectomy increased systolic blood pressure, which was only prevented by E2+DRSP treatment. Estrogen deficiency caused endothelial dysfunction, which was prevented by both treatments. However, the vasodilator response in the E2+DRSP group was significantly higher at the three highest concentrations compared with the OVX group. Reduced ER-α expression in OVX rats was restored by both treatments. Morphometric parameters and oxidative stress were augmented by OVX and reduced by E2 and E2+DRSP treatments. Hormonal therapy with E2 and DRSP may be an important therapeutic option in the prevention of coronary heart disease in hypertensive post-menopausal women.


Subject(s)
Animals , Female , Rats , Androstenes/administration & dosage , Coronary Vessels/drug effects , Endothelium, Vascular/drug effects , Estradiol/administration & dosage , Hormone Replacement Therapy/methods , Hypertension/drug therapy , Vasodilation/drug effects , Blotting, Western , Bradykinin/pharmacology , Combined Modality Therapy , Coronary Vessels/pathology , Estrogen Receptor alpha/drug effects , Estrogens/administration & dosage , Ethidium/analogs & derivatives , Femoral Artery , Hemodynamics , Mineralocorticoid Receptor Antagonists/administration & dosage , Nitric Oxide Synthase Type III/drug effects , Ovariectomy , Oxidative Stress/drug effects , Random Allocation , Rats, Inbred SHR , Vasodilator Agents/pharmacology
3.
Arq. neuropsiquiatr ; 73(2): 119-124, 02/2015. tab
Article in English | LILACS | ID: lil-741172

ABSTRACT

Neurological diseases are common in inflammatory bowel disease (IBD) patients, but their exact prevalence is unknown. Method We prospectively evaluated the presence of neurological disorders in 121 patients with IBD [51 with Crohn's disease (CD) and 70 with ulcerative colitis (UC)] and 50 controls (gastritis and dyspepsia) over 3 years. Results Our standard neurological evaluation (that included electrodiagnostic testing) revealed that CD patients were 7.4 times more likely to develop large-fiber neuropathy than controls (p = 0.045), 7.1 times more likely to develop any type of neuromuscular condition (p = 0.001) and 5.1 times more likely to develop autonomic complaints (p = 0.027). UC patients were 5 times more likely to develop large-fiber neuropathy (p = 0.027) and 3.1 times more likely to develop any type of neuromuscular condition (p = 0.015). Conclusion In summary, this is the first study to prospectively establish that both CD and UC patients are more prone to neuromuscular diseases than patients with gastritis and dyspepsia. .


Doenças neurológicas são comuns em pacientes com doença inflamatória intestinal (DII), mas sua prevalência exata é desconhecida. Métodos Nós estudamos prospectivamente a presença de distúrbios neurológicos em 121 pacientes com DII [51 com doença de Crohn (DC) e 70 com colite ulcerativa (RCU)] e 50 controles (gastrite e dispepsia) ao longo de 3 anos. Resultados A avaliação neurológica padronizada (que incluiu testes eletrodiagnósticos) demonstrou que pacientes com DC foram 7,4 vezes mais propensos a desenvolver neuropatias de fibras grossas do que os controles (p = 0,045), 7,1 vezes mais propensos a desenvolver qualquer tipo de condição neuromuscular (p = 0,001) e 5,1 vezes mais propensos a desenvolver queixas autonômicas (p = 0,027). Pacientes com RCU foram 5 vezes mais propensos de desenvolver neuropatia de fibras grossas (p = 0,027) e 3,1 vezes mais propensos a desenvolver qualquer tipo de condição neuromuscular (p = 0,015). Conclusão Em resumo, este é o primeiro estudo prospectivo a estabelecer que os pacientes tanto com DC quanto de RCU são mais propensos a doenças neuromusculares do que os pacientes com gastrite e dispepsia. .


Subject(s)
Animals , Female , Pregnancy , Anti-Inflammatory Agents/pharmacology , Dexamethasone/pharmacology , Microcirculation/drug effects , Muscle, Skeletal/blood supply , Prenatal Exposure Delayed Effects , Acetylcholine/pharmacology , Body Weight/drug effects , Bradykinin/pharmacology , Endothelium, Vascular/drug effects , Enzyme Inhibitors/pharmacology , Femoral Artery/drug effects , Femoral Artery/embryology , Microcirculation/embryology , NG-Nitroarginine Methyl Ester/pharmacology , Nitroprusside/pharmacology , Sheep , Vascular Resistance/drug effects , Vasoconstriction/drug effects , Vasodilation/drug effects , Vasodilator Agents/pharmacology
4.
Hist. ciênc. saúde-Manguinhos ; 21(4): 1475-1486, Oct-Dec/2014. tab, graf
Article in Spanish | LILACS | ID: lil-732506

ABSTRACT

Walter Álvarez Quispe, terapeuta kallawaya y biomédico especializado en cirugía general y ginecología, presenta la lucha de los terapeutas tradicionales y alternativos por la depenalización de estos sistemas médicos andinos realizada entre 1960 y 1990. Bolivia se torna el primer país en América Latina y el Caribe en despenalizar la medicina tradicional antes de los planteamientos de la Conferencia Internacional sobre Atención Primaria de Salud (Alma-Ata, 1978). Los datos aportados por el entrevistado aseguran que los logros alcanzados, principalmente por los kallawayas, responden a un proyecto propio y autónomo. Estas conquistas no se deben a las políticas oficiales de interculturalidad en salud, aunque busquen atribuirse para sí los logros alcanzados.


Walter Álvarez Quispe, a Kallawaya healer and biomedical practitioner specializing in general surgery and gynecology, presents the struggle of traditional and alternative healers to get their Andean medical systems depenalized between 1960 and 1990. Bolivia was the first country in Latin America and the Caribbean to decriminalize traditional medicine before the proposals of the International Conference on Primary Health Care (Alma-Ata, 1978). The data provided by the interviewee show that the successes achieved, mainly by the Kallawayas, stem from their own independent initiative. These victories are not the result of official policies of interculturality in healthcare, although the successes achieved tend to be ascribed to them.


Subject(s)
Animals , Guinea Pigs , Male , Bronchi/innervation , Bronchoconstriction/drug effects , Bronchoconstrictor Agents/pharmacology , Citric Acid/pharmacology , Neurons, Afferent/physiology , Sulfites/pharmacology , Administration, Inhalation , Acetylcholine/pharmacology , Airway Resistance/drug effects , Autacoids/pharmacology , Bradykinin/pharmacology , Calcitonin Gene-Related Peptide/metabolism , Citric Acid/administration & dosage , Hydrogen-Ion Concentration , Histamine/pharmacology , In Vitro Techniques , Lung Compliance/drug effects , Lung/innervation , Lung/metabolism , Neurokinin A/pharmacology , Neurons, Afferent/drug effects , Serotonin/pharmacology , Substance P/pharmacology , Sulfites/administration & dosage
5.
Clinics ; 67(8): 923-929, Aug. 2012. ilus, graf, tab
Article in English | LILACS | ID: lil-647797

ABSTRACT

OBJECTIVE: Ischemic preconditioning and some drugs can protect tissues from injury by preserving microcirculation. This study evaluated vascular permeability in a hamster cheek pouch preparation using either short ischemic periods or bradykinin as preconditioning stimuli followed by 30 min of ischemia/reperfusion. METHOD: Sixty-six male hamsters were divided into 11 groups: five combinations of different ischemic frequencies and durations (one, three or five shorts periods of ischemia, separated by one or five minutes) with 10 min intervals between the ischemic periods, followed by 30 min ischemia/reperfusion; three or five 1 min ischemic periods with 10 min intervals between them followed by the topical application of histamine (2 µM); bradykinin (400 nM) followed by 30 min of ischemia/reperfusion; and three control groups (30 min of ischemia/reperfusion or histamine or bradykinin by themselves). Macromolecular permeability was assessed by injection of fluorescein-labeled dextran (FITC-dextran, MW= 150 kDa; 250 mg/Kg body weight), and the number of leaks/cm2 was counted using an intravital microscope and fluorescent light in the cheek pouch. RESULTS: Plasma leakage (number of leaks/cm²) was significantly reduced by preconditioning with three and five 1 min ischemic periods, one and three 5 min ischemic periods and by bradykinin. Histamine-induced macromolecular permeability was also reduced after three periods of 5 min of ischemia. CONCLUSION: Short ischemic periods and bradykinin can function as preconditioning stimuli of the ischemia/reperfusion response in the hamster cheek pouch microcirculation. Short ischemic periods also reduced histamineinduced macromolecular permeability.


Subject(s)
Animals , Cricetinae , Male , Capillary Permeability/drug effects , Ischemic Preconditioning/methods , Reperfusion Injury/drug therapy , Bradykinin/pharmacology , Cheek/blood supply , Disease Models, Animal , Histamine Agonists/pharmacology , Histamine/pharmacology , Microcirculation , Plasma/drug effects , Plasma/physiology , Reperfusion Injury/blood , Time Factors , Treatment Outcome , Vasodilator Agents/pharmacology
6.
Braz. j. med. biol. res ; 41(2): 170-175, Feb. 2008. graf
Article in English | LILACS | ID: lil-474759

ABSTRACT

This study was undertaken in anesthetized dogs to evaluate the relative participation of prostaglandins (PGs) and nitric oxide (NO) in the maintenance of total renal blood flow (TRBF), and renal medullary blood flow (RMBF). It was hypothesized that the inhibition of NO should impair cortical and medullary circulation because of the synthesis of this compound in the endothelial cells of these two territories. In contrast, under normal conditions of perfusion pressure PG synthesis is confined to the renal medulla. Hence PG inhibition should predominantly impair the medullary circulation. The initial administration of 25 µM kg-1 min-1 NG-nitro-L-arginine methyl ester produced a significant 26 percent decrease in TRBF and a concomitant 34 percent fall in RMBF, while the subsequent inhibition of PGs with 5 mg/kg meclofenamate further reduced TRBF by 33 percent and RMBF by 89 percent. In contrast, the initial administration of meclofenamate failed to change TRBF, while decreasing RMBF by 49 percent. The subsequent blockade of NO decreased TRBF by 35 percent without further altering RMBF. These results indicate that initial PG synthesis inhibition predominantly alters the medullary circulation, whereas NO inhibition decreases both cortical and medullary flow. This latter change induced by NO renders cortical and RMBF susceptible to a further decrease by PG inhibition. However, the decrease in medullary circulation produced by NO inhibition is not further enhanced by subsequent PG inhibition.


Subject(s)
Animals , Dogs , Male , Kidney Cortex/blood supply , Kidney Medulla/blood supply , Nitric Oxide/physiology , Prostaglandins/physiology , Bradykinin/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Kidney Cortex/drug effects , Kidney Medulla/drug effects , Meclofenamic Acid/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Prostaglandin Antagonists/pharmacology , Regional Blood Flow/drug effects , Vasodilator Agents/pharmacology
7.
Clinics ; 63(5): 677-682, 2008. graf, tab
Article in English | LILACS | ID: lil-495044

ABSTRACT

INTRODUCTION: The evaluation of endothelial function has been performed in the arterial bed, but recently evaluation within the venous system has also been explored. Endothelial function studies employ different drugs that act as endothelium-dependent vasodilatory response inductors. OBJECTIVES: The aim of this study is to compare the endothelium-dependent venous vasodilator response mediated by either acetylcholine or bradykinin in healthy volunteers. METHODS AND RESULTS: Changes in vein diameter after phenylephrine-induced venoconstriction were measured to compare venodilation induced by acetylcholine or bradykinin (linear variable differential transformer dorsal hand vein technique). We studied 23 healthy volunteers; 31 percent were male, and the subject had a mean age of 33 ± 8 years and a mean body mass index of 23 ± 2 kg/m². The maximum endothelium-dependent venodilation was similar for both drugs (p = 0.13), as well as the mean responses for each dose of both drugs (r = 0.96). The maximum responses to acetylcholine and bradykinin also had good agreement. CONCLUSION: There were no differences between acetylcholine and bradykinin as venodilators in this endothelial venous function investigation.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Acetylcholine/pharmacology , Bradykinin/pharmacology , Endothelium, Vascular/drug effects , Endothelium-Dependent Relaxing Factors/pharmacology , Vasodilator Agents/pharmacology , Dose-Response Relationship, Drug , Endothelium, Vascular/physiology , Hand/blood supply , Nitroprusside/pharmacology , Phenylephrine/pharmacology , Veins/drug effects , Young Adult
8.
Braz. j. med. biol. res ; 40(5): 649-655, May 2007. graf, tab
Article in English | LILACS | ID: lil-449079

ABSTRACT

Previous studies have shown that the vascular reactivity of the mouse aorta differs substantially from that of the rat aorta in response to several agonists such as angiotensin II, endothelin-1 and isoproterenol. However, no information is available about the agonists bradykinin (BK) and DesArg9BK (DBK). Our aim was to determine the potential expression of kinin B1 and B2 receptors in the abdominal mouse aorta isolated from C57BL/6 mice. Contraction and relaxation responses to BK and DBK were investigated using isometric recordings. The kinins were unable to induce relaxation but concentration-contraction response curves were obtained by applying increasing concentrations of the agonists BK and DBK. These effects were blocked by the antagonists Icatibant and R-715, respectively. The potency (pD2) calculated from the curves was 7.0 ± 0.1 for BK and 7.3 ± 0.2 for DBK. The efficacy was 51 ± 2 percent for BK and 30 ± 1 percent for DBK when compared to 1 æM norepinephrine. The concentration-dependent responses of BK and DBK were markedly inhibited by the arachidonic acid inhibitor indomethacin (1 æM), suggesting a mediation by the cyclooxygenase pathway. These contractile responses were not potentiated in the presence of the NOS inhibitor L-NAME (1 mM) or endothelium-denuded aorta, indicating that the NO pathway is not involved. We conclude that the mouse aorta constitutively contains B1 and B2 subtypes of kinin receptors and that stimulation with BK and DBK induces contractile effect mediated by endothelium-independent vasoconstrictor prostanoids.


Subject(s)
Animals , Male , Mice , Aorta, Abdominal/drug effects , Bradykinin/agonists , Bradykinin/analogs & derivatives , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Receptor, Bradykinin B1/drug effects , /drug effects , Aorta, Abdominal/physiology , Bradykinin/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Indomethacin/pharmacology , Isometric Contraction/drug effects , Isometric Contraction/physiology , Receptor, Bradykinin B1/physiology , /physiology , Vasoconstriction/drug effects , Vasoconstriction/physiology
9.
Article in English | WPRIM | ID: wpr-106414

ABSTRACT

Diverse signaling pathways have been proposed to regulate store-operated calcium entry (SOCE) in a wide variety of cell types. However, it still needs to be determined if all of these known pathways operate in a single cell type. In this study, we examined involvement of various signaling molecules in SOCE using human fibroblast cells (HSWP). Bradykinin (BK)-stimulated Ca2+ entry, previously shown to be via SOCE, is enhanced by the addition of vanadate, an inhibitor of tyrosine phosphatases. Furthermore, SOCE is regulated by cytochrome P-450, as demonstrated by the fact that the products of cytochrome P-450 activity (14,15 EET) stimulated SOCE while econazole, an inhibitor of cytochrome P450, suppressed BK-stimulated Ca2+ entry. In contrast, Ca2+ entry was unaffected by the guanylate cyclase inhibitor LY83583, or the membrane permeant cyclic GMP analog 8-bromo-cyclic GMP (8-Br-cGMP). Neither nitric oxide donors nor phorbol esters affected BK-stimulated Ca2+ entry. SOCE in HSWP cells is primarily regulated by tyrosine phosphorylation and the cytochrome P-450 pathway, but not by cyclic GMP, nitric oxide, or protein kinase C. Thus, multiple pathways do operate in a single cell type leading to the activation of Ca2+ entry and some of these signaling pathways are more prominently involved in regulating calcium entry in different cell types.


Subject(s)
Vanadates/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Protein Tyrosine Phosphatases/metabolism , Phosphotyrosine/metabolism , Phosphorylation/drug effects , Nitric Oxide/metabolism , Humans , Fibroblasts , Epidermal Growth Factor/pharmacology , Enzyme Inhibitors/pharmacology , Econazole/pharmacology , Cytochrome P-450 Enzyme System/antagonists & inhibitors , Cyclic GMP/analogs & derivatives , Cells, Cultured , Calcium Channels/metabolism , Calcium/metabolism , Bradykinin/pharmacology
10.
Braz. j. med. biol. res ; 38(6): 959-966, June 2005. ilus, tab
Article in English | LILACS | ID: lil-402665

ABSTRACT

Discrepancy was found between enhanced hypotension and attenuated relaxation of conduit arteries in response to acetylcholine (ACh) and bradykinin (BK) in nitric oxide (NO)-deficient hypertension. The question is whether a similar phenomenon occurs in spontaneously hypertensive rats (SHR) with a different pathogenesis. Wistar rats, SHR, and SHR treated with NO donors [molsidomine (50 mg/kg) or pentaerythritol tetranitrate (100 mg/kg), twice a day, by gavage] were studied. After 6 weeks of treatment systolic blood pressure (BP) was increased significantly in experimental groups. Under anesthesia, the carotid artery was cannulated for BP recording and the jugular vein for drug administration. The iliac artery was used for in vitro studies and determination of geometry. Compared to control, SHR showed a significantly enhanced (P < 0.01) hypotensive response to ACh (1 and 10 æg, 87.9 ± 6.9 and 108.1 ± 5.1 vs 35.9 ± 4.7 and 64.0 ± 3.3 mmHg), and BK (100 æg, 106.7 ± 8.3 vs 53.3 ± 5.2 mmHg). SHR receiving NO donors yielded similar results. In contrast, maximum relaxation of the iliac artery in response to ACh was attenuated in SHR (12.1 ± 3.6 vs 74.2 ± 8.6 percent in controls, P < 0.01). Iliac artery inner diameter also increased (680 ± 46 vs 828 ± 28 æm in controls, P < 0.01). Wall thickness, wall cross-section area, wall thickness/inner diameter ratio increased significantly (P < 0.01). No differences were found in this respect among SHR and SHR treated with NO donors. These findings demonstrated enhanced hypotension and attenuated relaxation of the conduit artery in response to NO activators in SHR and in SHR treated with NO donors, a response similar to that found in NO-deficient hypertension.


Subject(s)
Animals , Male , Rats , Acetylcholine/pharmacology , Bradykinin/pharmacology , Hypotension/metabolism , Iliac Artery/drug effects , Nitric Oxide Donors/pharmacology , Vasodilator Agents/pharmacology , Blood Pressure/drug effects , Carotid Arteries/drug effects , Carotid Arteries/physiology , Hypotension/chemically induced , Iliac Artery/pathology , Iliac Artery/physiology , Molsidomine/pharmacology , Nitric Oxide Synthase/drug effects , Pentaerythritol Tetranitrate/pharmacology , Rats, Inbred SHR , Rats, Wistar
11.
Biol. Res ; 37(3): 419-430, 2004. graf
Article in English | LILACS | ID: lil-394436

ABSTRACT

In addition to the induction of cell proliferation and migration, bradykinin (BK) can increase c-fos mRNA expression, activate ERK 1/2 and generate reactive oxygen species (ROS) in vascular smooth muscle cells (VSMC). It is not known, however, whether BK can induce cellular proliferation and extracellular matrix production via redox-sensitive signaling pathways. We investigated the role(s) of ROS in proliferation, migration and collagen synthesis induced by BK in VSMC derived from Sprague Dawley rat aorta. BK (10 nM) increased VSMC proliferation by 30 % (n=5); this proliferation was inhibited by the antioxidants N-acetylcysteine (20 mM) and a-lipoic acid (LA, 250 mM). In addition, BK induced an increase in cell migration and in collagen levels that were blocked by LA. ROS production induced by BK (n=10) was significantly inhibited by bisindolylmaleimide (4mM) and by PD98059 (40mM). These results suggest that: 1) ROS participate in the mechanism(s) used by bradykinin to induce cellular proliferation; 2) bradykinin induces ROS generation through a pathway that involves the kinases PKC and MEK; and 3) ROS participate in the pathways mediating cell migration and the production of collagen as a response to treatment with bradykinin. To our knowledge, this is the first report describing mechanisms to explain the participation of ROS in the cellular proliferation and extracellular matrix pathway regulated by BK.


Subject(s)
Animals , Male , Rats , Antioxidants/pharmacology , Bradykinin/pharmacology , Cell Division/drug effects , Cell Movement/drug effects , Collagen/biosynthesis , Muscle, Smooth, Vascular/cytology , Reactive Oxygen Species , Aorta/cytology , Cells, Cultured , Rats, Sprague-Dawley
12.
Arq. gastroenterol ; 40(1): 40-44, Jan.-Mar. 2003. ilus, graf
Article in English | LILACS | ID: lil-347610

ABSTRACT

BACKGROUND: Although most studies have focused on the hepatocytes, all the hepatic cells participate in the regenerative process, among them the stellate cells. The stellate cells are mesenchymal cells involved in local neurotransmission and paracrine regulation of several liver functions. Acute hepatic tissue loss promotes the proliferation and activation of stellate cells from a quiescent state to myofibroblast-like cells. AIM: Investigate the effects of antihypertensive agents on the stellate cell population during the liver regenerative phenomenon in rats. METHODS: Adult male Wistar rats received lisinopril, losartan, bradykinin, or saline solution in a proportional volume, intraperitoneally, before and after 70 percent partial hepatectomy. Animals from the experimental and saline groups were sacrificed at 36 hours after partial hepatectomy. The alpha-smooth muscle actin labelled stellate cells population was counted in the periportal and pericentral zones of the liver specimen. RESULTS: The labelled stellate cells were more numerous in the control group both in the periportal and pericentral zones at 36 hours after partial hepatectomy than at the other times. The population of stellate cells was significantly lower in the losartan group and higher in the bradykinin and lisinopril groups than in the control group. CONCLUSIONS: These results suggest that losartan can inhibit and bradykinin and lisinopril can stimulate the stellate cell population during liver regeneration in rats. These cells synthesize several substances to stimulate liver regeneration.


Subject(s)
Animals , Male , Rats , Antihypertensive Agents/pharmacology , Liver Regeneration/drug effects , Liver/cytology , Bradykinin/pharmacology , Lisinopril/pharmacology , Losartan/pharmacology , Rats, Wistar
13.
Braz. j. med. biol. res ; 34(1): 125-7, Jan. 2001. ilus
Article in English | LILACS | ID: lil-277066

ABSTRACT

Bradykinin has been reported to act as a growth factor for fibroblasts, mesangial cells and keratinocytes. Recently, we reported that bradykinin augments liver regeneration after partial hepatectomy in rats. Angiotensin-converting enzyme (ACE) is also a powerful bradykinin-degrading enzyme. We have investigated the effect of ACE inhibition by lisinopril on liver regeneration after partial hepatectomy. Adult male Wistar rats underwent 70 percent partial hepatectomy (PH). The animals received lisinopril at a dose of 1 mg kg body weight-1 day-1, or saline solution, intraperitoneally, for 5 days before hepatectomy, and daily after surgery. Four to six animals from the lisinopril and saline groups were sacrificed at 12, 24, 36, 48, 72, and 120 h after PH. Liver regeneration was evaluated by immunohistochemical staining for proliferating cell nuclear antigen using the PC-10 monoclonal antibody. The value for the lisinopril-treated group was three-fold above the corresponding control at 12 h after PH (P<0.001), remaining elevated at approximately two-fold above control values at 24, 36, 48 (P<0.001), and at 72 h (P<0.01) after PH, but values did not reach statistical difference at 120 h after PH. Plasma ACE activity measured by radioenzymatic assay was significantly higher in the saline group than in the lisinopril-treated group (P<0.001), with 81 percent ACE inhibition. The present study shows that plasma ACE inhibition enhances liver regeneration after PH in rats. Since it was reported that bradykinin also augments liver regeneration after PH, this may explain the liver growth stimulating effect of ACE inhibitors


Subject(s)
Animals , Male , Rats , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Lisinopril/pharmacology , Liver Regeneration/drug effects , Angiotensin-Converting Enzyme Inhibitors/blood , Angiotensin-Converting Enzyme Inhibitors/metabolism , Bradykinin/pharmacology , Cell Division , Immunohistochemistry , Lisinopril/blood , Lisinopril/metabolism , Liver/cytology , Proliferating Cell Nuclear Antigen/analysis , Rats, Wistar , Renin-Angiotensin System/drug effects
14.
Braz. j. med. biol. res ; 33(9): 1089-92, Sept. 2000.
Article in English | LILACS | ID: lil-267969

ABSTRACT

In most of cells bradykinin (BK) induces intracellular calcium mobilization. In pancreatic beta cells intracellular calcium is a major signal for insulin secretion. In these cells, glucose metabolism yields intracellular ATP which blocks membrane potassium channels. The membrane depolarizes, voltage-dependent Ca2+ channels are activated and the intracellular calcium load allows insulin secretion. Repolarization occurs due to activation of the Ca2+-dependent K+ channel. The insulin secretion depends on the integrity of this oscillatory process (bursts). Therefore, we decided to determine whether BK (100 nM) induces bursts in the presence of a non-stimulatory glucose concentration (5.6 mM). During continuous membrane voltage recording, our results showed that bursts were obtained with 11 mM glucose, blocked with 5.6 mM glucose and recovered with 5.6 mM glucose plus 100 nM BK. Thus, the stimulatory process obtained in the presence of BK and of a non-stimulatory concentration of glucose in the present study suggests that BK may facilitate the action of glucose on beta cell secretion


Subject(s)
Animals , Mice , Bradykinin/pharmacology , Calcium/pharmacology , Glucose/metabolism , Insulin/metabolism , Islets of Langerhans/drug effects , Electrophysiology , Glucose/analysis , Insulin/metabolism , Islets of Langerhans/metabolism , Potassium Channels/metabolism
15.
Braz. j. med. biol. res ; 33(6): 709-13, Jun. 2000. graf
Article in English | LILACS | ID: lil-262039

ABSTRACT

It has been shown that angiotensin-(1-7) (Ang-(1-7)) infusion potentiates the bradykinin (BK)-induced hypotensive response in conscious rats. The present study was conducted to identify Ang-(1-7)-BK interactions in the isolated rat heart perfused according to the Langendorff technique. Hearts were excised and perfused through the aortic stump under a constant flow with Krebs-Ringer solution and the changes in perfusion pressure and heart contractile force were recorded. Bolus injections of BK (2.5, 5, 10 and 20 ng) produced a dose-dependent hypotensive effect. Ang-(1-7) added to the perfusion solution (2 ng/ml) did not change the perfusion pressure or the contractile force but doubled the hypotensive effect of the lower doses of BK. The BK-potentiating Ang-(1-7) activity was blocked by pretreatment with indomethacin (5 mg/kg, ip) or L-NAME (30 mg/kg, ip). The Ang-(1-7) antagonist A-779 (50 ng/ml in Krebs-Ringer) completely blocked the effect of Ang-(1-7) on BK-induced vasodilation. These data suggest that the potentiation of the BK-induced vasodilation by Ang-(1-7) can be attributed to the release of nitric oxide and vasodilator prostaglandins through an Ang-(1-7) receptor-mediated mechanism.


Subject(s)
Animals , Male , Rats , Angiotensin I/pharmacology , Bradykinin/pharmacology , Coronary Vessels/drug effects , Vasodilator Agents/pharmacology , Analysis of Variance , Cardiovascular Agents/pharmacology , Enzyme Inhibitors/pharmacology , Hypotension , Indomethacin/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide , Rats, Wistar
17.
Braz. j. med. biol. res ; 31(9): 1229-35, sept. 1998. graf
Article in English | LILACS | ID: lil-222970

ABSTRACT

The most conspicuous effect of bradykinin following its administration into the systemic circulation is a transient hypotension due to vasodilation. In the present study most of the available evidence regarding the mechanisms involved in bradykinin-induced arterial vasodilation is reviewed. It has become firmly established that in most species vasodilation in response to bradykinin is mediated by the release of endothelial relaxing factors following the activation of B2-receptors. Although in some cases the action of bradykinin is entirely mediated by the endothelial release of nitric oxide (NO) and/or prostacyclin (PGI2), a large amount of evidence has been accumulated during the last 10 years indicating that a non-NO/PGI2 factor accounts for bradykinin-induced vasodilation in a wide variety of perfused vascular beds and isolated small arteries from several species including humans. Since the effect of the non-NO/PGI2 endothelium-derived relaxing factor is practically abolished by disrupting the K+ electrochemical gradient together with the fact that bradykinin causes endothelium-dependent hyperpolarization of vascular smooth muscle cells, the action of such factor has been attributed to the opening of K+ channels in these cells. The pharmacological characteristics of these channels are not uniform among the different blood vessels in which they have been examined. Although there is some evidence indicating a role for KCa or KV channels, our findings in the mesenteric bed together with other reports indicate that the K+ channels involved do not correspond exactly to any of those already described. In addition, the chemical identity of such hyperpolarizing factor is still a matter of controversy. The postulated main contenders are epoxyeicosatrienoic acids or endocannabinoid agonists for the CB1-receptors. Based on the available reports and on data from our laboratory in the rat mesenteric bed, we conclude that the NO/PGI2-independent endothelium-dependent vasodilation induced by BK is unlikely to involve a cytochrome P450 arachidonic acid metabolite or an endocannabinoid agonist.


Subject(s)
Animals , Bradykinin/pharmacology , Endothelium-Dependent Relaxing Factors/physiology , Nitric Acid/metabolism , Prostaglandins/metabolism , Vasodilation/drug effects , Vasomotor System/drug effects , Bradykinin/adverse effects , Cytochrome P-450 Enzyme System/metabolism , Enzyme Inhibitors/metabolism , Hypotension/chemically induced , omega-N-Methylarginine/pharmacology , Potassium Channels/drug effects
20.
Indian J Physiol Pharmacol ; 1996 Oct; 40(4): 367-71
Article in English | IMSEAR | ID: sea-108697

ABSTRACT

Possible modulation of the Brewer's yeast-induced peripheral inflammation by two central neuropeptides, bradykinin and substance P (SP), was investigated in rats. Centrally administered bradykinin significantly increased pedal oedema and pain threshold whereas, SP produced significant augmentation of oedema volume and nociception. The results of the present study indicate that central bradykinin exerts pro-inflammatory and analgesic effects whereas, central SP exerts pro-inflammatory and pro-nociceptive effects on Brewer's yeast-induced peripheral inflammation.


Subject(s)
Analgesics/pharmacology , Animals , Bradykinin/pharmacology , Edema/drug therapy , Inflammation/drug therapy , Male , Pain/drug therapy , Rats , Rats, Sprague-Dawley , Saccharomyces cerevisiae , Substance P/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL